Insulet Corp

PODD

218.110USD

+2.110+0.98%

Close 03/26, 16:00（ET）Quotes delayed by 15 min

Insulet Corp's Score

Industry at a Glance

Industry Ranking

42 / 209

Overall Ranking

126 / 4546

Industry

Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Positive

Insulet Corp Highlights

StrengthsRisks

Insulet Corporation is a medical device company. It is primarily engaged in the development, manufacture and sale of its continuous insulin delivery systems for people with insulin-dependent diabetes. The Omnipod System includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5), the Omnipod DASH Insulin Management System, and the Omnipod Insulin Management System. The Omnipod platform offers continuous insulin delivery that provides various benefits of insulin pump therapy in a way without the need for external tubing required with conventional pumps. The small, lightweight, self-adhesive disposable tubeless Omnipod device (Pod), can be worn in multiple locations, including the abdomen, hip, back of upper arm, upper thigh, or lower back, and delivers insulin into the body through a small flexible tube. It also produces pods for Amgen for use in the Neulasta Onpro kit, a delivery system for Amgen’s Neulasta to help reduce the risk of infection after intense chemotherapy.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 59.57% year-on-year.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 2.71B.

Fairly Valued

The company’s latest PE is 62.09, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 71.89M shares, decreasing 4.49% quarter-over-quarter.

Held by CI Select Canadian Equity Fund

Star Investor CI Select Canadian Equity Fund holds 1.71K shares of this stock.

Analyst Rating

Based on 28 analysts

Buy

Current Rating

356.565

Target Price

+58.12%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Insulet Corp is 8.52, ranking 27 out of 209 in the Healthcare Equipment & Supplies industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 783.80M, representing a year-over-year increase of 31.18%, while its net profit experienced a year-over-year increase of 0.89%.

Score

Industry at a Glance

Previous score

8.52

Change

0



Financials

9.05

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

8.67

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

8.58

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

8.91

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.41

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Insulet Corp is 3.60, ranking 201 out of 209 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is 62.09, which is 76641.23% below the recent high of 47652.24 and 48.53% above the recent low of 31.96.

Score

Industry at a Glance

Previous score

3.60

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 42/209

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Insulet Corp is 8.57, ranking 21 out of 209 in the Healthcare Equipment & Supplies industry. The average price target is 380.00, with a high of 432.00 and a low of 316.00.

Score

Industry at a Glance

Previous score

8.57

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Insulet Corp is 6.65, ranking 118 out of 209 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 242.07 and the support level at 204.70, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.47

Change

0.18

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-03-26

The current institutional shareholding score of Insulet Corp is 10.00, ranking 1 out of 209 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 102.19%, representing a quarter-over-quarter decrease of 0.19%. The largest institutional shareholder is The Vanguard, holding a total of 8.67M shares, representing 12.31% of shares outstanding, with 0.30% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

8.76M

+1.00%

Fidelity Management & Research Company LLC

6.91M

+0.85%

BlackRock Institutional Trust Company, N.A.

4.43M

+1.72%

Capital Research Global Investors

4.55M

-3.95%

State Street Investment Management (US)

3.09M

+1.11%

Baillie Gifford & Co.

Star Investors

2.09M

-2.03%

Geode Capital Management, L.L.C.

1.97M

+1.96%

American Century Investment Management, Inc.

1.41M

+7.42%

ClearBridge Investments, LLC

1.47M

-4.52%

Fidelity International

1.11M

-1.69%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Insulet Corp is 7.62, ranking 36 out of 209 in the Healthcare Equipment & Supplies industry. The company's beta value is 1.46. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.

Insulet Corp

PODD

7.48 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Anika Therapeutics Inc

ANIK

8.64 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Thermo Fisher Scientific Inc

TMO

8.48 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Bioventus Inc

BVS

8.37 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

West Pharmaceutical Services Inc

WST

8.26 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Lantheus Holdings Inc

LNTH

8.12 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment